Newtyn Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,873,694
| Closed | -$27.7M | – | 49 |
|
|
2024
Q1 | $27.7M | Hold |
1,873,694
| – | – | 5.51% | 5 |
|
|
2023
Q4 | $25.1M | Hold |
1,873,694
| – | – | 4.93% | 5 |
|
|
2023
Q3 | $23.1M | Hold |
1,873,694
| – | – | 5.7% | 4 |
|
|
2023
Q2 | $23M | Hold |
1,873,694
| – | – | 5.44% | 6 |
|
|
2023
Q1 | $23M | Buy |
1,873,694
+105,300
| +6% | +$1.24M | 4.52% | 6 |
|
|
2022
Q4 | $20.3M | Buy |
1,768,394
+1,300
| +0.1% | +$10.7K | 4.18% | 7 |
|
|
2022
Q3 | $6.63M | Buy |
1,767,094
+9,089
| +0.5% | +$42K | 1.45% | 23 |
|
|
2022
Q2 | $10.5M | Buy |
1,758,005
+44,393
| +3% | +$250K | 1.98% | 19 |
|
|
2022
Q1 | $10.8M | Buy |
1,713,612
+164,729
| +11% | +$925K | 2.59% | 17 |
|
|
2021
Q4 | $6.06M | Hold |
1,548,883
| – | – | 1.61% | 24 |
|
|
2021
Q3 | $7.48M | Hold |
1,548,883
| – | – | 2% | 20 |
|
|
2021
Q2 | $9.87M | Hold |
1,548,883
| – | – | 2.73% | 14 |
|
|
2021
Q1 | $9.7M | Hold |
1,548,883
| – | – | 2.62% | 15 |
|
|
2020
Q4 | $10.7M | Buy |
1,548,883
+252,447
| +19% | +$1.24M | 2.46% | 15 |
|
|
2020
Q3 | $5.19M | Buy |
1,296,436
+96,830
| +8% | +$356K | 1.26% | 28 |
|
|
2020
Q2 | $4M | Buy |
1,199,606
+26,440
| +2% | +$90.2K | 1.46% | 28 |
|
|
2020
Q1 | $2.52M | Hold |
1,173,166
| – | – | 0.87% | 37 |
|
|
2019
Q4 | $3.69M | Hold |
1,173,166
| – | – | 0.34% | 38 |
|
|
2019
Q3 | $5.27M | Sell |
1,173,166
-367,469
| -24% | -$1.84M | 0.5% | 33 |
|
|
2019
Q2 | $7.33M | Buy |
1,540,635
+85,870
| +6% | +$407K | 0.95% | 25 |
|
|
2019
Q1 | $7.96M | Buy |
1,454,765
+325,329
| +29% | +$1.5M | 1.5% | 22 |
|
|
2018
Q4 | $3.43M | Buy |
1,129,436
+271,511
| +32% | +$942K | 0.67% | 28 |
|
|
2018
Q3 | $3.6M | Buy |
857,925
+53,005
| +7% | +$223K | 0.62% | 25 |
|
|
2018
Q2 | $3.11M | Buy |
804,920
+625,891
| +350% | +$4.16M | 0.58% | 21 |
|
|
2018
Q1 | $1.13M | Sell |
179,029
-281,499
| -61% | -$2.33M | 0.2% | 21 |
|
|
2017
Q4 | $3.71M | Sell |
460,528
-35,162
| -7% | -$328K | 0.57% | 19 |
|
|
2017
Q3 | $5.67M | Buy |
+495,690
| New | +$5.21M | 0.92% | 18 |
|
Other funds holding MACK
RA
JC
Newtyn Management's MACK Position: Q2 2024 in Review
Newtyn Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 1,873,694 shares — an estimated $27.7M sold.
Newtyn Management first reported a position in MACK in Q3 2017 and held it in 27 quarters. The position peaked at $27.7M in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Newtyn Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Newtyn Management sold 1,873,694 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $27.7M.
- Newtyn Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2017 and held it in 27 quarters.
- Newtyn Management's Merrimack Pharmaceuticals, Inc. position peaked at $27.7M in Q1 2024.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.